NCT04483310 (MR_Therapy) is a NA clinical trial of MR therapy. in Sleep Paralysis, sponsored by Azienda Usl di Bologna.

Who is sponsoring NCT04483310?

NCT04483310 is sponsored by Azienda Usl di Bologna.

What drugs are being tested in NCT04483310?

Interventions in NCT04483310: MR therapy., breathing-distraction exercise.

What condition does NCT04483310 study?

NCT04483310 studies Sleep Paralysis, Narcolepsy Type 1.

Is NCT04483310 still recruiting?

NCT04483310 is currently status unknown. Last updated 23 July 2020.

Last reviewed 2020-07-23 · How we verify

NCT04483310: MR_Therapy

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Meditation-Relaxation (MR Therapy) for Sleep Paralysis.

Status unknown NA Last updated 23 July 2020

What this trial tests

NA trial testing MR therapy. in Sleep Paralysis in 20 participants. Status unknown.

Timeline

1 December 2018

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Azienda Usl di Bologna
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 December 2018
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across Italy

Drugs / interventions tested

MR therapy.
breathing-distraction exercise

Conditions studied

Sleep Paralysis — all drugs for Sleep Paralysis →
Narcolepsy Type 1 — all drugs for Narcolepsy Type 1 →

Sponsor

Azienda Usl di Bologna — full company profile →

Who can join

Adults 18 to 65, any sex, with Sleep Paralysis or Narcolepsy Type 1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to evaluate, with a small-scale pilot study, the efficacy of Meditation Relaxation therapy for Sleep Paralyses in patients with narcolepsy. The study involves two arms, with intervention with Meditation Relaxation therapy or sham over a period of three months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Azienda Usl di Bologna trials

Trials by the same sponsor.

NCT07492511 — Renal and Hepatic Abnormal Doppler Patterns in Trauma · recruiting
NCT06742645 — The Use of Brief Motivational Interviewing in Community Health Centers. · NA · recruiting
NCT06395558 — intErnet-based iNterventions FOR Cardiac arrEst suRvivors · NA · recruiting
NCT06471231 — Renal Outcomes in the Early Use of Vasopressin in the Treatment of Septic Shock · Phase 4 · recruiting
NCT06750822 — Accuracy of Automatic Contusion Volume Scanning for Predicting the Incidence of Pneumonia in Patients With Thoracic Trau · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04483310 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Azienda Usl di Bologna
Last refreshed: 23 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04483310.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing